Neuroprotective Role of Agmatine in Neurological Diseases
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Neurological diseases have always been one of the leading cause of mobility and mortality world-widely. However, it is still lacking efficient agents. Agmatine, an endogenous polyamine, exerts its diverse biological characteristics and therapeutic potential in varied aspects. METHODS: This review would focus on the neuroprotective actions of agmatine and its potential mechanisms in the setting of neurological diseases. RESULTS: Numerous studies had demonstrated the neuroprotective effect of agmatine in varied types of neurological diseases, including acute attack (stroke and trauma brain injury) and chronic neurodegenerative diseases (Parkinson's disease, Alzheimer's disease). The potential mechanism of agmatine induced neuroprotection includes anti-oxidation, anti-apoptosis, anti-inflammation, brain blood barrier (BBB) protection and brain edema prevention. CONCLUSIONS: The safety and low incidence of adverse effects indicate the vast potential therapeutic value of agmatine in the treatment of neurological diseases. However, most of the available studies relate to the agmatine are conducted in experimental models, more clinical trials are needed before the agmatine could be extensively clinically used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810 · cited 1×
“Its pathological hallmarks are extracellular deposition of amyloidbeta peptide, and presence of neurofibrillary tangles in the neuron [59] which are mainly distributed in the hippocampus, cerebral cortex and basal ganglia [60, 61].”
BackgroundMolecular and cellular immune mediators of neuroprotection
Turrin, N. P., & Rivest, S. (2006) · Molecular Neurobiology · doi:10.1385/mn:34:3:221 · Cited by 85 · cited 1×
“Under normal conditions, inflammation could help to scavenge the necrotic cells or tissues, and initiate the tissue repair process [104].”
BackgroundStudies with {? 2}-adrenoceptor agonists and alcohol abstinence syndrome in rats
Parale, M. P., & Kulkarni, S. K. (1986) · Psychopharmacology · doi:10.1007/bf00652247 · Cited by 38
Cited by
Huang, F., Pariante, C. M., & Borsini, A. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.09.021 · Cited by 117
Aglawe, M. M., Kale, M. B., Rahangdale, S. R., Kotagale, N. R., Umekar, M. J., & Taksande, B. G. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.11.015 · Cited by 40
Reversal of lipopolysaccharide-induced learning and memory deficits by agmatine in mice
Borikar, S. P., Dongare, S. I., & Danao, K. R. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1830086 · Cited by 28
“Agmatine, an endogenous polycationic amine synthesized from L-arginine by arginine decarboxylase, is known to rescue CNS neurons from various in vitro and in vivo experimental neuronal injuries [11–14] Several experimental studies demonstrated that agmatine reduced neuronal damage in various CNS injuries like ischemia…”
Background
Metadata
- Authors
- Xu, W., Gao, L., Li, T., Shao, A., & Zhang, J.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2018-10-05
- Volume
- 16
- Issue
- 9
- Pages
- 1296-1305
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2744369125
- Cited by
- 87
- References
- 4
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotective Role of Agmatine in Neurological Diseases. https://app.cochat.ai/papers/10.2174/1570159x15666170808120633
- The paper
- Xu, W., Gao, L., Li, T., Shao, A., & Zhang, J. (2018). Neuroprotective Role of Agmatine in Neurological Diseases. Current Neuropharmacology. https://doi.org/10.2174/1570159x15666170808120633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.